Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Published version of a preprint
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodies. The three antibodies were compared in assays measuring direct cell death (AnnexinV/PI staining and time-lapse microscopy), complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and internalization. The models used for the comparison of their activity in vivo were SU-DHL4 and RL xenografts. GA101 was found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it was 10 to 1,000 times less potent in mediating CDC. GA101 showed superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and was comparable with these two in ADCP. GA101 also showed slower internalization rate upon binding to CD20 than rituximab and ofatumumab. In vivo, GA101 induced a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. When rituximab-pretreated animals were used, second-line treatment with GA101 was still able to control tumor progression, whereas tumors escaped rituximab treatment. Taken together, the preclinical data show that the glyoengineered type II CD20 antibody GA101 is differentiated from the two approved type I CD20 antibodies rituximab and ofatumumab by its overall preclinical activity, further supporting its clinical investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD20-targeting mAbs such as rituximab, obinutuzumab, ocaratuzumab, and ofatumumab”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Herter et al., 2013
In the citing paper
“a variety of mAbs targeting malignant cells mediate immunostimulation upon the engagement of ADCC, ADCP, or complement-dependent cytotoxicity”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Herter et al., 2013
Citations
Cites
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540 · cited 1×
“The introduction of rituximab into clinical practice has markedly advanced the treatment of hematologic malignancies (17-19).”
BackgroundMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981 · cited 7×
“Antitumor activity in an SU-DHL4 and RL xenograft model We have previously shown that GA101 mediates dosedependent efficacy in the SU-DHL4NHLxenograftmodel in SCID beige mice, with complete tumor remission observedwithGA101at doses of 30mg/kg (1).”
BackgroundMethodResultInfluentialSelf-citationFerrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770 · cited 1×
“Obinutuzumab (GA101) is a novel type II, humanized, CD20 mAb that has been glycoengineered to reduce core fucosylation, conferring enhanced affinity for the human FcγRIIIa receptor on effector cells and, hence, enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) (1, 2).”
BackgroundSelf-citationTeeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609 · cited 2×
“epitope onCD20, involving both the small and large loops of CD20 (5, 11, 12).”
BackgroundMarcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5376 · Cited by 594 · cited 1×
“The introduction of rituximab into clinical practice has markedly advanced the treatment of hematologic malignancies (17-19).”
BackgroundC1q: Structure, function, and receptors
Kishore, U., & Reid, K. B. M. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80301-x · Cited by 479 · cited 1×
“Type I antibodies are believed to induce higher levels of CDC than type II antibodies owing to stronger binding of type I antibody/CD20 complexes within lipid rafts to C1q, the first subcomponent of classical complement activation (22, 23).”
BackgroundAntibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360 · cited 1×
“Type I antibodies are believed to induce higher levels of CDC than type II antibodies owing to stronger binding of type I antibody/CD20 complexes within lipid rafts to C1q, the first subcomponent of classical complement activation (22, 23).”
BackgroundBeers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
Research works printed but not linked: 2
- Engelberts, 2010, Ofatumumab targets a conformational membrane-proximal epitope which contains amino acids located in the small and large loops of CD20, Haematol-Hematol J, 95, 46
- Beurskens, 2010, NK cell binding and induction of potent NK cell-mediated ADCC by ofatumumab, a new human CD20 monoclonal antibody [abstract], Haematologica, 95, 173
Cited by
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
“Hepatic or biliary 39 (16) 21 (18) 40 (17) 21 (18) 56 (17) 66 (20)”
InfluentialAcute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Metadata
- Authors
- Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M., & Klein, C.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Authors' Affiliations: 1Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France
- Lyon 1 Université (FR)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-10-01
- Volume
- 12
- Issue
- 10
- Pages
- 2031-2042
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2135802989
- Cited by
- 366
- References
- 39
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 20 · 2023: 24 · 2022: 27 · 2021: 26 · 2020: 24 · 2019: 34 · 2018: 28 · 2017: 34 · 2016: 29 · 2015: 41 · 2014: 23 · 2013: 3
- FWCI
- 23.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Roche Innovation Center Zurich
- University of Leicester
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- obinutuzumab, rituximab, ofatumumab, anti-CD20 monoclonal antibody, glycoengineering, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, B-cell depletion, antibody internalization, rituximab resistance, non-Hodgkin lymphoma
- MeSH terms
- Rituximab, Animals, Antibodies, Monoclonal, Cytotoxicity, Immunologic, Humans, Neoplasms, Phagocytosis, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Murine-Derived, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1182
- The paper
- Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., . . . Klein, C. (2013). Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.